Cara Therapeutics discontinues NP program after oral difelikefalin fails Part A of KOURAGE-1 study

Tvardi Therapeutics, Inc.

Oral difelikefalin did not demonstrate meaningful clinical benefit at any dose vs. placebo in Part A of KOURAGE-1 study for notalgia paresthetica.
Company discontinues clinical program in NP and will explore strategic alternatives to maximize shareholder value.
Cash, cash equivalents, and marketable securities were approximately $70 million as of March 31, 2024.
Drug was well tolerated; safety profile similar to prior trials. Part A enrolled 214 patients across four arms.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.